BeiGene Ltd - ADR

NASDAQ:BGNE   3:58:54 PM EDT
325.27
+3.46 (+1.08%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)29.93B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$178.52 Million
Adjusted EPS-$3.41
See more estimates
10-Day MA$335.02
50-Day MA$329.43
200-Day MA$305.98
See more pivots

BeiGene Ltd - ADR Stock, NASDAQ:BGNE

Zhongguancun Life Science Park, No. 30 Science Park Road, Beijing, Beijing 102206
Cayman Islands
Phone: +86.10.58958000
Number of Employees: 5300

Description

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.